Elimusertib (Bay 1895344) is an experimental

anticancer An anticarcinogen (also known as a carcinopreventive agent) is a substance that counteracts the effects of a carcinogen or inhibits the development of cancer. Anticarcinogens are different from anticarcinoma agents (also known as anticancer or ant ...

drug which acts as an inhibitor of

ataxia telangiectasia and Rad3 related Serine/threonine-protein kinase ATR, also known as ataxia telangiectasia and Rad3-related protein (ATR) or FRAP-related protein 1 (FRP1), is an enzyme that, in humans, is encoded by the ''ATR'' gene. It is a large kinase of about 301.66 kDa. ATR ...

protein. This is involved in DNA repair following damage, and so inhibiting this protein causes cancer cells to become more vulnerable to other chemotherapy drugs. Elimusertib is in early stage

clinical trial Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...

s against advanced solid tumors.

References

{{reflist Experimental cancer drugs Kinase inhibitors Morpholines Naphthyridines Pyrazoles